Biopharmx corp (BPMX)
CashFlow / Yearly
Jan'20Jan'19Jan'18Jan'17Jan'16Dec'14Dec'13Sep'13Dec'12Sep'12Sep'11
Cash flows from operating activities:
Net loss

-9,687

-17,258

-16,640

-18,406

-

-

-

-

-

-

-59

Net loss

-

-

-

-

-15,598

-7,807

-1,588

-

-88

-

-

Net loss for the period

-

-

-

-

-

-

-

-52

-

-27

-

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

741

2,061

1,887

1,491

1,214

1,193

58

-

9

-

-

Fair value of modification of warrants

308

874

151

-

436

-

-

-

-

-

-

Depreciation expense

61

62

52

141

56

25

5

0

1

0

0

Amortization of note discount

13

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and stock liabilities

291

28

-

-

-

-

-

-

-

-

-

Impairment loss on property and equipment

78

-

-

-

-

-

-

-

-

-

-

Amortization expense

-

-

-

119

30

0

-

-

-

-

-

Warrants issued for services provided

-

-

-

-

-

99

-

-

-

-

-

Non-cash interest expense

-

-

-

145

-

76

74

-

5

-

-

Change in fair value of warrant liability

-

-

364

163

-

-

-

-

-

-

-

Other non-cash expense

-

3

-

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable

-

-

-

-3

6

2

-

-

-

-

-

Inventories

-

-

-

-62

-60

138

-

-

-

-

-

Prepaid expenses and other assets

-63

32

-75

68

46

133

-184

-

-1

-

-

Accounts payable

-799

-13

-1,175

774

625

257

-

-

-

-

-

Accrued expenses and other liabilities

-594

-661

427

156

608

355

-

44

-

16

53

Accounts payable and accrued expenses

-

-

-

-

-

-

446

-

14

-

-

Related party payables

-

-

-

-

7

74

109

-

9

-

-

Net cash used in operating activities

-

-

-

-

-12,614

-6,001

-

-

-

-

-

Increase in accrued interest - related party

-

-

-

-

-

-

-

0

-

0

-

Net cash used in operating activities

-10,107

-14,992

-15,587

-15,746

-

-

-1,080

-7

-51

-10

-5

Cash flows from investing activities:
Change in restricted cash

-

-

-

-

-

35

-

-

-

-

-

Purchases of property and equipment

30

43

41

45

38

228

25

0

13

0

0

Net cash used in investing activities

-30

-43

-41

-45

-

-

-85

0

-13

0

-0

Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs

7,200

-

-

-

-

-

0

-

0

-

-

Purchase of intellectual property

-

-

-

-

-

-

60

-

0

-

-

Net cash used in investing activities

-

-

-

-

-38

-263

-

-

-

-

-

Proceeds from the issuance of common stock, preferred stock and warrants, net of issuance costs

-

-

16,049

16,712

13,316

-

-

0

-

0

15

Proceeds from exercises of common stock warrants

-

10,546

644

-

1,487

-

-

-

-

-

-

Proceeds from exercises of stock options

4

1

10

41

83

99

-

-

-

-

-

Payments on financing lease obligation

34

19

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of convertible redeemable preferred stock and common stock warrants

-

-

-

-

-

7,253

-

-

-

-

-

Repurchase of common stock

-

-

-

-

-

-

0

-

0

-

-

Proceeds from issuance of convertible notes, net

-

-

-

1,500

500

1,020

1,030

-

200

-

-

Net cash provided by financing activities

-

-

-

-

15,386

8,372

-

-

-

-

-

Proceeds from issuance of note payable

625

-

-

-

-

-

-

2

-

0

-

Net cash provided by financing activities

7,795

10,528

16,703

18,253

-

-

1,030

2

200

-

15

Net decrease in cash and cash equivalents

-2,342

-4,507

-

-

-

-

-

-

-

-

-

Non-cash investing activities:
Net increase (decrease) in cash and cash equivalents

-

-

1,075

2,462

2,734

2,108

-135

-

136

-

-

Property and equipment acquired through finance lease

54

61

-

-

-

-

-

-

-

-

-

Non-cash financing activities:
Conversion of Series A convertible preferred stock to common stock

-

-

1,515

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

7,226

-

-

-

-

-

-

Fair value of beneficial conversion feature issued in connection with convertible notes payable

-

-

-

-

-

-

206

-

40

-

-

Intellectual assets purchase accrued

-

-

-

-

-

-

90

-

0

-

-

Issuance of warrants in connection with note payable

460

-

-

1,645

-

1,847

-

-

-

-

-

Fair value of common stock liability reclassed to accrued expenses and other

663

-

-

-

-

-

-

-

-

-

-

Fair value of beneficial conversion feature issued in connection with convertible notes

-

-

-

88

-

204

-

-

-

-

-

Deemed dividend on Series A convertible preferred stock

-

-

-

126

-

-

-

-

-

-

-

Supplemental disclosures:
Interest paid

-

-

-

-

-

-

-

0

-

0

0

Income taxes paid

-

-

-

-

4

-

-

0

-

0

0

NET INCREASE IN CASH

-

-

-

-

-

-

-

-4

-

-10

8

Income taxes paid

2

2

2

2

-

-

-

-

-

-

-